Celluminova develops proprietary research tools and technologies to analyze stem cell behavior with applications in cancer stem cell studies and translational biomedical research. The company operates in the research infrastructure segment rather than developing therapeutics, supplying precision tools to laboratories and academic institutions. Its technologies aim to improve the reliability of experimental models and reduce time required for preclinical studies, addressing challenges in modeling rare and complex cell populations. Celluminova is based in Linköping, Sweden. With SEK 20 million in new funding, the company plans to commercialize its product portfolio, expand its technical team, and grow its market presence across Europe and North America.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026